



Give Uta Hope, Give Her a Future – Stand with Her Against Childhood Cancer

Cost of the new drug:
¥60,000,000
(approx. \$400,000)



▲ Instagram



▲ Save Uta HP

※QR Links are all in Japanese.

Uta was diagnosed with childhood cancer (neuroblastoma) at age two.

After 19 months of painful treatment, she finally left the hospital.

But with a high risk of relapse, her fight isn't over.

A new drug approved in the U.S. offers real hope—but it's not available in Japan and must be privately imported at a huge cost.

It's far beyond what our family can afford.

We dream of seeing Uta grow up and share everyday moments together.

Please, give her the chance to keep fighting.

We humbly ask for your support.

About IWILFIN (Eflornithine)

IWILFIN is a new FDA-approved drug (Dec 2023) for **high-risk neuroblastoma**.

It reduces the **risk of relapse by 52%** and **death by 68%**—offering real hope to children like Uta.

But it's not available in Japan and must be **imported at full cost** by families.



The Danger of High-Risk Neuroblastoma

High-risk neuroblastoma is an aggressive childhood cancer that often spreads quickly and is difficult to treat. Children go through intense treatments—chemotherapy, surgery, stem cell transplants—but even then, **more than 50% relapse**.

Once it comes back, the survival rate drops to **less than 10%**.

That's why **preventing relapse is critical**, and why access to new treatments like **IWILFIN** offers real hope.

Donate by Bank Transfer ※ SMBC users: send to “ウタチャンオスクウカイ”

AWA BANK (code:0172)
Matsushige branch (305)
(Ordinary) 1255812
Account Name: ウタチャンオスクウカイ

Donate by credit card here
Crowdfunding : ForGood

※ Campaign Period:
April 12 – June 8, 2025



Save Uta HP URL: <https://www.save-utachan.com/>

※QR Links are all in Japanese.